SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs acknowledged affair and Nvidias independent board investigation, prompted by reports linking the woman to suspected Chinese intelligence activity, drove concern about leadership stability and possible security risks. Traders debated whether the controversy could materially affect Nvidia or was a temporary distraction, with many viewing the share-price drop as a buying opportunity and others wary of further fallout.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is rallying ahead of its quarterly report, with traders speculating that results or guidance could improve and that heavy short interest may fuel further covering. Optimismpartly tied to strong results at ad-tech peersis tempered by skepticism about slowing growth and the stocks history of sharp post-earnings declines.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Jefferies Buy initiation and favorable Phase III prostate cancer data are drawing attention to Candels planned BLA filing for CAN-2409. Bulls see the results and recent immune-profile data as support for the regulatory case, while skeptics question filing execution, manufacturing readiness, financing needs and management transparency.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics Q3 results and higher revenue outlook, driven by BRIUMVI growth, dominate discussion, but the shares sold off despite the positive report. Traders debate whether this is a sell-the-news reaction or short-driven pressure, while many point to Phase 3 data for subcutaneous BRIUMVI as the next major catalyst.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

QNX and Valeos smart-camera platform, which has secured design wins with multiple Chinese automakers and is expected to enter production this year, is fueling attention alongside BlackBerrys broader automotive and robotics software story. Traders are optimistic about future growth from QNX adoption, while skeptics question how quickly that adoption will translate into meaningful revenue and point to the stocks continued volatility.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXOs rally is being tied to preliminary third-quarter results that traders viewed as strong, along with bullish remarks from CEO Brad Jacobs. Many are cheering the rebound and speculating about short covering, while others remain cautious after the stocks steep decline and amid concerns about acquisition integration.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs stronger-than-expected quarterly results and raised full-year revenue outlook are driving attention, with traders also pointing to expanding backlog and quantum-computing demand. Bulls see evidence of commercial momentum, while skeptics question dilution, cash burn and how much growth came from the SkyWater acquisition, keeping the reaction volatile.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims is in focus ahead of its quarterly results as traders weigh the Eli Lilly agreement to offer branded obesity drugs through its platform against concerns that the shift could pressure margins. The sharp decline has fueled speculation about disappointing results or an earnings leak, while others see the partnership and potential growth as reasons to stay bullish.

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Clover Health Investments Corp

Clover shares are drawing attention after a sharp, high-volume move above a closely watched resistance level, with traders focused on whether the breakout will hold. The move follows a quarterly earnings beat and improved full-year outlook, though investors disagree on the upside until Counterparts software business shows clearer external revenue.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two is drawing attention ahead of GTA VIs anticipated launch, with traders focused on expected sales, preorders, and the potential for recurring revenue from GTA Online. Bulls see substantial upside, while skeptics argue the hype may already be priced in and worry about a sell-the-news reaction, release risks, and upcoming earnings guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MoonLakes BLA filing for sonelokimab in hidradenitis suppurativa has put the upcoming FDA acceptance and review decision in focus; traders are weighing the drugs clinical results against regulatory uncertainty, including concerns about a prior trial miss. The discussion is also divided over whether MoonLake can commercialize on its own or may need a partner or buyer.

Healthcare Stocks Ignite: Oncology Pushes, Breakout Battles, and Next Big Growth Catalysts

Healthcare stocks are heating up, and investors have a fresh lineup of catalysts to watch. Pfizer (NYSE:PFE) is pushing its oncology story back into the spotlight, while NeOnc Technologies Holdings (NASDAQ:NTHI) is emerging as a high-volatility biotech to watch as brain-cancer milestones, Abu Dhabi expansion and a battle around key technical levels converge. Avantor (NYSE:AVTR) faces a crucial earnings test that could determine whether its recovery has more room to run, while Eli Lilly and Co (NYSE:LLY) is building on its blockbuster drug franchise with encouraging new pediatric clinical data. Takeda Pharmaceutical (NYSE:TAK) brings global pipeline potential and diversified drug-market exposure to the mix, while MoonLake Immunotherapeutics (NASDAQ:MLTX) is drawing trader attention with active trading putting its next potential catalyst under the microscope.

MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near

Equity

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.


MoonLake's Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.read more...

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’

At week 16, 42.1% of patients on Sonelokimab achieved at least a 50% improvement in psoriatic arthritis symptoms, meeting the trial’s primary endpoint.


MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data  

MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis. 


Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

The consensus price target hints at a 73.4% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears

SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.

MoonLake Immunotherapeutics' CFO Sells 39K Shares

Key PointsThe executive sold 39,120 shares on June 22...

MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa

MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa...

Why MoonLake Immunotherapeutics Stock Wilted on Wednesday

Key PointsIt aims to raise up to $200 million in the offering...

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

Bullish Sentiment

<ul class="summary-bullets"><li>MoonLake plans to file with the U.S. Food and Drug Administration (FDA) by the end of September, seeking permission to sell sonelokimab for hidradenitis suppurativa.&nbsp;</li><li>By late November, the FDA should say whether it accepted the filing, whether it will review it faster, and when it will decide.</li><li>Three shots are already approved for HS: AbbVie’s Humira, Novartis’s Cosentyx, and UCB’s Bimzelx.</li></ul><p>Shares of MoonLake Immunotherapeutics (MLTX) slid about 15% this week as investors marked down the stock weeks before a planned U.S. filing for its lead drug.</p><p>MLTX &nbsp;has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock about 80% below its 52-week high. The stock is on track to clock its worst week in about a year, if losses hold.</p><h2 class="st-heading-2">Filing Date Looms</h2><p>MoonLake plans to file with the U.S. Food and Drug Administration (FDA) by the end of September, seeking permission to sell sonelokimab for hidradenitis suppurativa, a painful condition that causes boils and tunnels under the skin. The request would cover both adults and teens. The agency has already said the existing studies can support a filing.</p><p>By late November, the FDA should say whether it accepted the file, whether it will review it faster, and when it will decide. A standard review would point to a possible U.S. launch in the second half of 2027.</p><h2 class="st-heading-2">What The Drug Did In Trials</h2><p>Sonelokimab is an experimental injection that blocks two proteins that drive inflammation. After one year in two late-stage studies, about two-thirds of adults had a large drop in skin lesions and about one-third saw their lesions disappear. Early data in teens looked similar. Safety matched earlier studies.</p><p>Doubt remains because the first look at the data, at four months, was mixed. One study succeeded. The second missed its main goal after patients on dummy treatment improved more than expected, a setback that crushed the stock a year ago. The FDA, however, later said MoonLake did not need new skin-disease trials.</p><p>In August, a late-stage study of the drug in patients with psoriatic arthritis also hit its main goal.</p><h2 class="st-heading-2">A Crowded Market</h2><p>Three shots are already approved for HS: AbbVie’s Humira, Novartis’s Cosentyx, and UCB’s Bimzelx. Other new drugs are also in development.</p><p>MoonLake says its drug design and long-term trial results can help it stand out, but it would enter a market where rivals already have years of real-world use.</p><h2 class="st-heading-2">Next Catalysts</h2><p>MoonLake ended June with $537 million in cash, enough, it says, to last into mid-2028. It has no approved product and lost $131.5 million in the first half of 2026.</p><p>The nearest catalyst for the stock is the hidradenitis filing. A second late-stage joint-disease study should finish enrolling this quarter, with results later this year. MoonLake also plans to start a late-stage trial in palmoplantar pustulosis, which has no approved U.S. treatment.</p><h2 class="st-heading-2">How Did MLTX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around MLTX stock stayed ‘neutral’ over the past 24 hours, while message volume was ‘high.’</p><p>A Stocktwits user said that shorts are resorting to bashing the company for its perceived lack of announcements, as they have no arguments against its drug.</p><p><stembedurl>https://stocktwits.com/Modern_portholio_theory/message/664081954</stembedurl></p><p>Another user opined that even with approval for sonelokimab, the company will enter a crowded market. “Yes the pie is big but it will &nbsp;be divided into many little pieces. $20 is already a lot for this company,” they wrote.</p><p><stembedurl>https://stocktwits.com/Antocar/message/664076232</stembedurl></p><p>Certain analysts, however, are more bullish. Last month, H.C. Wainwright raised the firm's price target on MoonLake Immunotherapeutics to $50 from $45 and kept a Buy rating on the shares after increasing its probabilities of approval to 70% from 60% in hidradenitis suppurativa, to 60% from 50% in psoriatic arthritis, and to 50% from 40% in axial spondyloarthritis.</p><p><a href="https://stocktwits.com/symbol/MLTX">MLTX stock</a> has fallen 3% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dell-hpe-stocks-lead-s-and-p-500-gains-oracle-s-95-b-capex-plan-lifts-ai-stocks/cZtXFJxRBb2">DELL, HPE Stocks Lead S&amp;P 500 Gains: Oracle’s $95B Capex Plan Lifts AI Stocks</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the MoonLake Immunotherapeutics (Moon Lake) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high.

MoonLake Immunotherapeutics

T Rowe Price Capital Appreciation Equity ETF

Vanguard Health Care ETF

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits Polls

Investors are closely watching the upcoming FDA BLA acceptance decision in late November as the primary catalyst for a major stock move.

Traders are highlighting the recent failure of a major competitor's trial as validation for their own clinical data and competitive edge.

New bullish analyst initiations, including an aggressive $57 price target, are fueling speculation of massive upside potential.

Current Price	$12.58
Prev Close	$11.53
Open	$11.82
Dividend Yield	0.00%
50-Day Moving Average	$12.11
Beta	0.73
Avg. Volume	1.97M
PE Ratio	-3.14

52-Week High	$23.29
52-Week Low	$9.46
Market Capitalization	$981.28M
EPS (Annual)	-$3.53
Price to Book	2.57
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

MLTX Fundamentals